COPD, severe early onset
Therapeutic area
Pulmonology
Rare disease
No
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- COPD, severe early onset
- Therapeutic area
- Pulmonology
- COPD, severe early onset
- COPD
- pulmonary disease, chronic obstructive
- COPD, rate of decline of lung function in
- COPD, severe early-onset
- pulmonary disease, chronic obstructive, severe early-onset
- All therapeutic areas
- Pulmonology
- Severity
- Unknown
- Genetic
- Hereditary
- MONDO ID
- MONDO:0011751
- Parent condition
- MONDO:0003847
Related records
Broader conditions (13)
- Chronic obstructive pulmonary disease
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Human disease
- Lower respiratory tract disorder
- Lung disorder
- Obstructive lung disease
- Respiratory system disorder
- Tracheal disorder
- Upper respiratory tract disorder
Trials (5,279)
- : Vascular Function in Health and Disease
- 'Real Life' Monitoring of COPD no ICS Patients
- "Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"
- "First-in-human" Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers
- "The Effect of Inhaled Nitroglycerin for COPD Patients
- (Cost-)Effectiveness Interdisciplinary Community-based COPD Management Program (INTERCOM)
- (In)Voluntary Assessed Quadriceps Muscle Endurance in COPD
- 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
- 12 / 48 Week Pivotal PFT vs PBO in COPD I
- 12 / 48 wk Pivotal PFT vs PBO in COPD II
- 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
- 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
- 12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
- 12-week Efficacy of Indacaterol
- 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
- 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
- 14729-D9831C00002- 1 Month Biopsy Study
- 15-year Mortality After Hospitalization for Exacerbation of Chronic Obstructive Pulmonary Disease
- 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients